Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.55 |
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6929421 | 1.00 | ALDH1A1 (0.56) | ALDH1A1KMT2AMEN1POLBTP53 | |
| SCHEMBL6929458 | 0.89 | NPC1 (0.57) | KMT2AMEN1POLBMAPTTDP1 | |
| SCHEMBL6929457 | 0.89 | NPC1 (0.57) | KMT2AMEN1POLBMAPTTDP1 | |
| SCHEMBL6929929 | 0.86 | MITF (0.59) | ALDH1A1KMT2AMEN1POLBMAPT | |
| SCHEMBL6929674 | 0.86 | POLB (0.57) | ALDH1A1KMT2AMEN1POLBMAPT | |
| SCHEMBL6929932 | 0.86 | MITF (0.59) | ALDH1A1KMT2AMEN1POLBMAPT | |
| SCHEMBL6929675 | 0.86 | POLB (0.57) | ALDH1A1KMT2AMEN1POLBMAPT | |
| SCHEMBL6930113 | 0.86 | NPC1 (0.61) | KMT2AMEN1POLBMAPTUSP2 | |
| SCHEMBL6930112 | 0.86 | NPC1 (0.61) | KMT2AMEN1POLBMAPTUSP2 | |
| SCHEMBL6932582 | 0.85 | NR1H4 (0.60) | KMT2AMEN1POLBMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624196-B2 | Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | claimed |
| US-6541521-B1 | Particularly gelatinase A, collagenase-3, and stromelysin-1 | WARNER-LAMBERT COMPANY | 2003-04-01 | — | — | US | claimed |
| US-20020161050-A1 | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 2002-10-31 | — | — | US | claimed |
| US-6624196-B2 | Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-6541521-B1 | Particularly gelatinase A, collagenase-3, and stromelysin-1 | WARNER-LAMBERT COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020161050-A1 | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161050-A1 | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | MMP1, MMP8, MMP13 | ALDH1A1 1135/4885KMT2A 4700/4885MEN1 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.